Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Weight Loss on Prostate Cancer Pathology

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00475982
First received: May 17, 2007
Last updated: September 26, 2014
Last verified: September 2014
  Purpose

The purpose of this study is to determine if weight loss prior to radical prostatectomy effects chemical substances in the blood stream and prostate tissue that may affect prostate cancer development and progression.


Condition Intervention
Obesity
Prostate Cancer
Behavioral: Weight Loss
Other: No Weight Loss Group

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Effect of Weight Loss on Prostate Cancer Pathology

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • Apoptotic index of the highest Gleason grade malignant epithelium in the radical prostatectomy specimen obtained after 8-weeks of the dietary intervention [ Time Frame: 9-1-2013 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proliferative index in prostate cancer epithelium specimen, change in apoptotic & proliferative indices of malignant epithelium between the diagnostic prostate needle biopsy & corresponding radical prostatectomy, change in serum IGF-related analytes [ Time Frame: 9-1-2013 ] [ Designated as safety issue: No ]

Enrollment: 44
Study Start Date: January 2009
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
Weight Loss Group
Behavioral: Weight Loss
Subjects undergo a weight loss intervention prior to radical prostatectomy. The intervention includes weekly visits with the dietician, DEXA scanning, blood draws, and anthropometrics.
Active Comparator: Arm 2
No Weight Loss Group
Other: No Weight Loss Group
These subjects do not undergo a weight loss intervention prior to radical prostatectomy. This group does undergo DEXA scanning, blood draws, and anthropometrics prior to radical prostatectomy.

Detailed Description:

Obesity is an epidemic, a major public health concern, and is a significant risk factor for progression and mortality from prostate cancer. Prior work in our laboratory in pre-clinical prostate cancer models and in obese men found that a low fat diet, exercise, and weight loss resulted in antiproliferative and pro-apoptotic effects on prostate cancer tissue through mechanisms related to the IGF-axis. We now propose to conduct a prospective, randomized clinical trial in overweight and obese men with prostate cancer undergoing radical prostatectomy to evaluate if weight loss prior to radical prostatectomy results in antiproliferative and pro-apoptotic effects in prostate cancer tissue. We will accomplish this aim by enrolling overweight and obese men with prostate cancer scheduled to undergo radical prostatectomy. Following informed consent, men will be randomized to either immediate radical prostatectomy or to an 8-week weight loss intervention group that will undergo a diet and exercise weight loss program followed by radical prostatectomy. Proliferation and apoptosis of prostate cancer cells in the prostatectomy specimen will be compared between the groups and relative to the baseline prostate needle biopsy specimens. Further studies will evaluate potential serum surrogate biomarkers that we developed in our laboratory (ex-vivo serum bioassays) and serum and tissue IGF-axis proteins that have previously been related to obesity, weight loss, and prostate cancer progression. The goal of our project will be to evaluate the potential anticancer effects of weight loss on prostate cancer tissue and to identify surrogate serum biomarkers that reflect antiproliferative and pro-apoptotic tissue effects and can be applied to future secondary prevention trials in overweight and obese prostate cancer survivors.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is overweight or obese (BMI > 25 kg/m2)
  • Patient with pathologically confirmed adenocarcinoma of the prostate and has elected to undergo radical prostatectomy
  • Willing to delay radical prostatectomy for 5 to 8-weeks if randomized to the weight loss intervention group.
  • Able to adhere to physical activity intervention (able to walk for 30 minutes without rest)
  • Able to come to the VA for weight loss visits during the 5 to 8-wk study

Exclusion Criteria:

  • Any one of the following: Gleason grade > 4+4, PSA > 20.
  • History of ever receiving androgen deprivation therapy, antiandrogen therapy, or finasteride
  • Prior prostate radiotherapy (external beam or brachytherapy) or prior cryotherapy
  • Diagnosis of diabetes mellitus and on insulin**
  • Current use of weight loss medications or enrolled in a diet/weight loss program
  • Current use of lycopene supplements*** Significant co-morbidities (i.e. cardiac, pulmonary, liver disease, ongoing alcohol/drug abuse) Cardiac pacemaker
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00475982

Locations
United States, California
VA Greater Los Angeles Healthcare System, West LA
West Los Angeles, California, United States, 90073
Sponsors and Collaborators
Investigators
Principal Investigator: William Aronson, MD VA Greater Los Angeles Healthcare System, West LA
  More Information

No publications provided

Responsible Party: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00475982     History of Changes
Other Study ID Numbers: CLIN-012-06F
Study First Received: May 17, 2007
Last Updated: September 26, 2014
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Diet
Insulin-like Growth Factor
Weight Loss

Additional relevant MeSH terms:
Prostatic Neoplasms
Weight Loss
Body Weight
Body Weight Changes
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Signs and Symptoms
Urogenital Neoplasms

ClinicalTrials.gov processed this record on November 27, 2014